BioVie Inc. announced the appointment of Joseph M. Palumbo, MD, LFAPA, MACPsych, as the company?s new Chief Medical Officer. In this role Dr. Palumbo will oversee the Company?s clinical development and operations activities, including the advancement of NE3107, an oral small molecule, blood-brain permeable modulator of ERK and NFkB expected to modulate neuroinflammation and insulin resistance, while still facilitating the homeostatic function inherent to their mechanisms. He will also be responsible for the development of BIV201, an active agent used in over 40 countries to treat complications of liver cirrhosis, that is not yet available in either the US or Japan. Dr. Palumbo joins BioVie from Zynerba Pharmaceuticals, where he was also Chief Medical Officer responsible for clinical operations, development, regulatory, and medical affairs.